Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
46actual
Sites
13
Countries
Belgium, Italy, Spain +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-05 | actual | When the study began enrolling |
| Primary completion | 2025-10-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-13 | actual | The whole study's end, after follow-up |
| First posted | 2022-10-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Malignancies
Intervention
- Drug: INCA32459-101
Primary outcomes
what the primary-completion date above is the date OFPart 1: Occurrence of Dose Limiting Toxicities (DLTs)
measured Up to approximately 12 months
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
measured Up to approximately 12 months
Number of Participants with Dose Interruptions due to TEAE
measured Up to approximately 12 months
Number of Participants discontinue study due to TEAE
measured Up to approximately 12 months
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed